- All News
- In the News
- Press Releases
- Noteworthy Articles
Deadly Infections Drive Billions in Hospital Bills to Medicare
Life-threatening complications from bacterial infections are on the rise among hospital patients, increasing at a double-digit rate as the population ages and costing U.S. health-care programs billions of dollars a year. Severe sepsis was the second most frequently billed diagnosis submitted by hospitals with more than 398,000 cases. By Caroline...
Immunexpress to Submit Molecular ‘Immune Response’ Sepsis Assay to FDA in May
Immunexpress may finally be close to marketing a clinical test in the US. Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, the company plans to submit the test in May to the US Food and Drug Administration and hopes it can...
Immunexpress vying for FDA clearance of its sepsis test
When it comes right down to detecting sepsis most diagnostics companies use methods to identify the pathogen. But therein lies the issue with looking for the pathogen, because it has to be in the blood sample or the fluid sample to start with, otherwise a clinician can't find. That's where...
Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour
Seattle diagnostics company Immunexpress is working to whittle sepsis screening time down to an hour – and is in the midst of a $40 million Series C to do so.
Immunexpress Receives Early Stage Commercialisation Support to Further Develop SeptiCyte® PLUS
Immunexpress receives Early Stage Commercialisation support to further develop SeptiCyte®PLUS — designed to diagnose sepsis accurately within a clinically relevant timeframe. BRISBANE, Australia (February 18, 2014) – Today, Immunexpress Group (Immunexpress) announced it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD...
Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection
Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent...
Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients
Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes SEATTLE, United States / EINDHOVEN, The Netherlands (April 10, 2013) –Today, the Immunexpress Group announced its collaboration...
Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection
Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection SEATTLE, United States (November 21, 2012) – Today, Immunexpress Group announced the granting in the United States (U.S.) of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment.”...
Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis
Sutherland et al., Critical Care | A novel molecular biomarker test based on a panel of 42-gene expression markers has demonstrated a clinically relevant sensitivity and specificity profile, and has the capacity for early detection of sepsis via the monitoring of critical care patients.